British small-cap stocks are currently undervalued and ripe for investment, according to analysis from the Henderson Smaller Companies investment trust, which argues that a decade of economic turbulence has left the sector “awash with value.” The trust, which specialises in identifying growth in UK-listed companies before their potential is fully priced in, says that disciplined valuation work reveals a host of opportunities where share prices do not yet reflect strong fundamentals in growth and cash generation.
The past ten years have been punishing for British small caps, beginning with nerves around the EU referendum and culminating in the energy crisis and a sharp rise in interest rates. That period has left the sector unloved and overlooked — but it has also created a deep well of value. UK small-cap stocks are trading at historically low valuations, with the forward price-to-earnings ratio sitting at just over 10 times, well below the long-term average of 14 times, according to market data. This undervaluation persists even in companies with strong fundamentals and growth prospects.
Corporate buyers have taken notice. A surge in merger and acquisition activity has seen larger entities capitalise on low valuations, often acquiring small caps at a premium to their current market price. That trend, combined with shifting macroeconomic conditions — potential interest rate cuts, structural growth themes, and improving investor sentiment — points towards an inflection point for the sector. The November 2025 budget also lent support by adjusting ISA allowances to make stocks and shares ISAs more attractive relative to cash ISAs, a policy designed to channel investment into equities, including smaller companies.
Three small-cap picks with deep value
Oxford Biomedica (LSE: OXB) is a contract development and manufacturing organisation (CDMO) specialising in viral vectors for cell and gene therapy — treatments used to combat cancer and rare genetic diseases. It is one of only a handful of global players capable of developing these technologies at commercial scale. The market for viral vector manufacturing is growing at more than 20% a year, and Oxford Biomedica has set ambitious targets to more than double revenues by 2028, supported by new capacity at its facilities in Oxford and Durham, US. Despite faster forecast sales and earnings growth than many internationally listed peers, its shares trade at about a 30% discount to those peers. The company’s negative earnings — reflected in a price-to-earnings ratio of -23.40 — make a direct P/E comparison difficult, but analysts have given it a consensus “Moderate Buy” rating, with six buy ratings and one hold. The consensus 12-month price target of £8.43 implies a potential upside of 36% from current levels. The valuation case is further strengthened by meaningful consolidation across the CDMO sector in recent years and reported interest from private-equity firm EQT. The global CDMO market was valued at over $255bn in 2025 and is projected to exceed $580bn by 2034, growing at a compound annual rate of nearly 10%.
Rathbones (LSE: RAT) provides financial planning and investment advice in a world where financial-services firms are fighting to get closer to their clients. Ageing populations and rising personal and wealth taxes are driving demand for its services, which include bespoke investment management, retirement planning, tax reduction, and inheritance tax management. The shares trade at a steep discount to the multiples paid in recent precedent transactions — most notably the £2.7bn acquisition of smaller competitor Evelyn Partners by NatWest Group. That deal highlights the strategic value and consolidation underway in the wealth management sector. Rathbones offers an attractive dividend yield of approximately 5.15%. Its price-to-earnings ratio of 18.56 is above the financial services sector average of 16.39, but analysts argue the stock is still cheap relative to the M&A benchmark. The consensus rating is “Buy,” with six buy ratings, two holds and one sell, and the average 12-month price target of roughly £2,328.90 points to further upside. Revenues for the full year 2025 rose nearly 35% to £1.21bn, and there has been insider buying in the past three months, with two directors purchasing shares.
Everplay (LSE: EVPL), the independent video-game developer and publisher formerly known as Team17, operates a business model designed for resilience. In the premium “AA” and “AAA” segment of the market, large studios sink huge sums into individual titles and rely on blockbuster hits. Everplay, by contrast, spends an average of £1m to £1.5m per game and releases about ten new titles a year, diversifying risk so earnings are not dependent on any single release. Roughly 75% of its earnings come from a strong back catalogue of well-known titles — Worms, for example, is more than 20 years old and still generates revenue. The company also owns simulation-gaming business Astragon, which serves a niche customer base, and StoryToys, a mobile “edutainment” division targeting younger players and recurring revenues. Despite resilient growth and strong cash generation — the company held net cash of £31.87m — Everplay shares trade at just over seven times EV/Ebitda, a significant discount to peers, precedent transactions and its own history. The trailing P/E ratio is 7.01, and the forward P/E is 9.44. Analysts have a consensus “Buy” rating with six buy ratings and no holds or sells, and a consensus price target of GBX 430.83, representing approximately 71% upside from the current price of GBX 252. The company has firepower for further acquisitions, having recently taken a 20% minority stake in Super Media Group, which includes UK-based FPS developer Bulkhead. The UK video-game market reached a record £8.76bn in consumer spending in 2025, having doubled over the past decade, with subscription services and recurring revenue models driving growth.
Disciplined valuation at the core
The Henderson Smaller Companies investment trust’s stock-picking approach is designed to identify growth before others do, capturing what it calls the “small-cap premium” through disciplined valuation. The trust invests only where prices do not yet fully reflect a company’s strong fundamentals in terms of growth and cash generation. That discipline, applied across a sector currently trading well below its historical norms, underpins the conviction that British small caps are not just unloved — they are a rare opportunity for long-term capital and income growth.
